Compare TAYD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | PLX |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 182.9M |
| IPO Year | 1995 | 1996 |
| Metric | TAYD | PLX |
|---|---|---|
| Price | $58.84 | $2.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.3K | ★ 701.9K |
| Earning Date | 10-02-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.14 | ★ 0.27 |
| Revenue | $41,649,673.00 | ★ $52,744,000.00 |
| Revenue This Year | $40.70 | $55.77 |
| Revenue Next Year | $13.65 | N/A |
| P/E Ratio | $418.36 | ★ $10.04 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.50 | $1.60 |
| 52 Week High | $90.37 | $3.19 |
| Indicator | TAYD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 55.26 |
| Support Level | $57.54 | $2.59 |
| Resistance Level | $62.30 | $2.75 |
| Average True Range (ATR) | 2.42 | 0.09 |
| MACD | -0.43 | -0.01 |
| Stochastic Oscillator | 46.10 | 50.10 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.